CoChat

Structures of the CDK12/CycK complex with AMP-PNP reveal a flexible C-terminal kinase extension important for ATP binding

Open access

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

Cyclin-dependent kinase 12 (CDK12) promotes transcriptional elongation by phosphorylation of the RNA polymerase II C-terminal domain (CTD). Structure-function studies show that this activity is dependent on a C-terminal kinase extension, as well as the binding of cyclin K (CycK). To better define these interactions we determined the crystal structure of the human CDK12/CycK complex with and without the kinase extension in the presence of AMP-PNP. The structures revealed novel features for a CDK, including a large β4-β5 loop insertion that contributes to the N-lobe interaction with the cyclin. We also observed two different conformations of the C-terminal kinase extension that effectively open and close the ATP pocket. Most notably, bound AMP-PNP was only observed when trapped in the closed state. Truncation of this C-terminal structure also diminished AMP-PNP binding, as well as the catalytic activity of the CDK12/CycK complex. Further kinetic measurements showed that the full length CDK12/CycK complex was significantly more active than the two crystallised constructs suggesting a critical role for additional domains. Overall, these results demonstrate the intrinsic flexibility of the C-terminal extension in CDK12 and highlight its importance for both ATP binding and kinase activity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep17122

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Soluble expression of CDK12 requires CycK. (a) Schematic showing the domain organisation of human CDK12 and CycK (RS, arginine-serine-rich; PRM, proline-rich motifs). (b) Small scale nickel-affinity purifications from 3 mL baculoviral expression of hexahistidine-tagged proteins. Results are shown for a subset of experiments using the indicated CDK12 constructs as well as CycK11–267 and CycL143–320. (c) Deconvoluted intact mass spectra for CDK12715–1052 purified following co-expression with CycK11–267. The two mass peaks represent the native protein as well as a larger species containing a single phosphorylation on CDK12 Thr893. (d) Deconvoluted intact mass spectra for CDK12715–1038 obtained before and after treatment with recombinant CAK from Candida albicans. The shorter CDK12 construct is essentially unphosphorylated until CAK treatment.
Figure 1 Soluble expression of CDK12 requires CycK. (a) Schematic showing the domain organisation of human CDK12 and CycK (RS, arginine-serine-rich; PRM, proline-rich motifs). (b) Small scale nickel-affinity purifications from 3 mL baculoviral expression of hexahistidine-tagged proteins. Results are shown for a subset of experiments using the indicated CDK12 constructs as well as CycK11–267 and CycL143–320. (c) Deconvoluted intact mass spectra for CDK12715–1052 purified following co-expression with CycK11–267. The two mass peaks represent the native protein as well as a larger species containing a single phosphorylation on CDK12 Thr893. (d) Deconvoluted intact mass spectra for CDK12715–1038 obtained before and after treatment with recombinant CAK from Candida albicans. The shorter CDK12 construct is essentially unphosphorylated until CAK treatment.CC BY · PubMed Central
Figure 2 Three distinct structural states of the CDK12/CycK complex. (a) Ribbon representation overview of the complex structures of CDK12715–1038/CycK11–267 and CDK12715–1052/CycK11–267. CDK12 is coloured green, except for the C-terminal kinase extension shown in pink. CycK is coloured light brown. The C-terminal kinase extension, including αK, adopts distinct packing conformations in the different chains in the CDK12715–1052/CycK11–267 structure. AMP-PNP, included in all crystallisations, is observed only in chain A of this structure where its binding is stabilized by the C-terminal extension. All CDK12 subunits were phosphorylated on Thr893 (shown by sticks). (b) Superposition of the CDK12 chains from available crystal structures. In addition to changes in the C-terminal region, there are subtle differences in the packing of the glycine-rich loop, the β4-β5 loop and the tilt of the αC helix. (c) Superposition of the CycK chains from available crystal structures. The apo-structure of CycK (PDB ID: 2I53) shows differences to the complex structures in the region of the H4’ helix in the second cyclin box as well as in the N and C-termini.
Figure 2 Three distinct structural states of the CDK12/CycK complex. (a) Ribbon representation overview of the complex structures of CDK12715–1038/CycK11–267 and CDK12715–1052/CycK11–267. CDK12 is coloured green, except for the C-terminal kinase extension shown in pink. CycK is coloured light brown. The C-terminal kinase extension, including αK, adopts distinct packing conformations in the different chains in the CDK12715–1052/CycK11–267 structure. AMP-PNP, included in all crystallisations, is observed only in chain A of this structure where its binding is stabilized by the C-terminal extension. All CDK12 subunits were phosphorylated on Thr893 (shown by sticks). (b) Superposition of the CDK12 chains from available crystal structures. In addition to changes in the C-terminal region, there are subtle differences in the packing of the glycine-rich loop, the β4-β5 loop and the tilt of the αC helix. (c) Superposition of the CycK chains from available crystal structures. The apo-structure of CycK (PDB ID: 2I53) shows differences to the complex structures in the region of the H4’ helix in the second cyclin box as well as in the N and C-termini.CC BY · PubMed Central
Figure 3 Structural features of the active CDK12 subunit (a) Ribbon representation highlighting selected structural features of the CDK12715–1052 subunit bound to AMP-PNP (PDB ID 4CXA, chain A). (b) CDK12 adopts an active conformation as shown by the correct alignment of the hydrophobic spine (indicated residues shown as spheres). (c) Phosphorylation at CDK12 Thr893 helps to stabilize the active kinase conformation. Shown are the hydrogen bond interactions of pThr893 with Arg882 (activation loop) and Arg858 (catalytic loop) as well as the nearby interaction of Arg773 (PITAIRE motif, αC helix) with CycK Glu108. (d) Ovarian cancer-associated mutations28 that impair CDK12 activity are mapped onto the structure and are predicted to destabilize the protein fold. Sites of mutation are indicated as spheres. CycK is omitted for clarity.
Figure 3 Structural features of the active CDK12 subunit (a) Ribbon representation highlighting selected structural features of the CDK12715–1052 subunit bound to AMP-PNP (PDB ID 4CXA, chain A). (b) CDK12 adopts an active conformation as shown by the correct alignment of the hydrophobic spine (indicated residues shown as spheres). (c) Phosphorylation at CDK12 Thr893 helps to stabilize the active kinase conformation. Shown are the hydrogen bond interactions of pThr893 with Arg882 (activation loop) and Arg858 (catalytic loop) as well as the nearby interaction of Arg773 (PITAIRE motif, αC helix) with CycK Glu108. (d) Ovarian cancer-associated mutations28 that impair CDK12 activity are mapped onto the structure and are predicted to destabilize the protein fold. Sites of mutation are indicated as spheres. CycK is omitted for clarity.CC BY · PubMed Central
Figure 4 Side chain interactions in the CDK12/CycK interface (a) Binding of the CDK12 β4-β5 loop to CycK. Shown is a superposition of the two complexes in the asymmetric unit of the CDK12715–1052/CycK11–267 structure (CDK12 chain A and CycK chain B are coloured green and light brown, respectively, whereas chains C and D are coloured gray). A structure-based sequence alignment (right panel) reveals the insertion in the β4-β5 loop of CDK12 and CDK13 as well as the sequence divergence across this region and the interacting H5 helix of CycK. The positions of displayed residues participating in hydrophobic (ϕ) and hydrogen bond (*) interactions are marked under the alignment. (b) Hydrophobic interactions define the core of the protein-protein interface. (c) Electrostatic interactions cluster outside the core interface.
Figure 4 Side chain interactions in the CDK12/CycK interface (a) Binding of the CDK12 β4-β5 loop to CycK. Shown is a superposition of the two complexes in the asymmetric unit of the CDK12715–1052/CycK11–267 structure (CDK12 chain A and CycK chain B are coloured green and light brown, respectively, whereas chains C and D are coloured gray). A structure-based sequence alignment (right panel) reveals the insertion in the β4-β5 loop of CDK12 and CDK13 as well as the sequence divergence across this region and the interacting H5 helix of CycK. The positions of displayed residues participating in hydrophobic (ϕ) and hydrogen bond (*) interactions are marked under the alignment. (b) Hydrophobic interactions define the core of the protein-protein interface. (c) Electrostatic interactions cluster outside the core interface.CC BY · PubMed Central
Figure 5 Alternative conformations of the CDK12 C-terminal extension. (a) Superposition of the two CDK12715–1052 subunits in the asymmetric unit (PDB ID: 4CXA). An asterisk marks the point at which the two chains diverge following Leu1025. In chain A (green and bright pink), the C-terminal extension folds in front of the ATP pocket, whereas in chain C (gray and pale pink) the C-terminus extends across the back of the kinase domain. (b) Superposition reveals that the αK helix is stably formed in both chains despite their alternative packing arrangements. (c) Molecular surface representation of chains A and B highlighting the enclosure of the bound AMP-PNP molecule by the C-terminal kinase extension. Coloured as in Fig. 2. (d) Selected interactions of the C-terminal kinase extension packing at the front of the ATP pocket (CDK12 chain A).
Figure 5 Alternative conformations of the CDK12 C-terminal extension. (a) Superposition of the two CDK12715–1052 subunits in the asymmetric unit (PDB ID: 4CXA). An asterisk marks the point at which the two chains diverge following Leu1025. In chain A (green and bright pink), the C-terminal extension folds in front of the ATP pocket, whereas in chain C (gray and pale pink) the C-terminus extends across the back of the kinase domain. (b) Superposition reveals that the αK helix is stably formed in both chains despite their alternative packing arrangements. (c) Molecular surface representation of chains A and B highlighting the enclosure of the bound AMP-PNP molecule by the C-terminal kinase extension. Coloured as in Fig. 2. (d) Selected interactions of the C-terminal kinase extension packing at the front of the ATP pocket (CDK12 chain A).CC BY · PubMed Central
Figure 6 CDK12 truncations show diminished activity against the RNA Pol II CTD. Comparison of in vitro kinase activity against a GST-CTD substrate by various CDK12 complexes and CDK9/Cyclin T1 (FL denotes full length proteins). A representative autoradiograph detecting 32P-GST-CTD product is shown together with a graphic representation of 3 biological replicates of each phosphorylation reaction.
Figure 6 CDK12 truncations show diminished activity against the RNA Pol II CTD. Comparison of in vitro kinase activity against a GST-CTD substrate by various CDK12 complexes and CDK9/Cyclin T1 (FL denotes full length proteins). A representative autoradiograph detecting 32P-GST-CTD product is shown together with a graphic representation of 3 biological replicates of each phosphorylation reaction.CC BY · PubMed Central
Figure 7 Determination of CDK12 kinetic parameters. (a) Full length CDK12/CycK1 activity was measured against varying concentrations of ATP over 3 time points (15 min, 30 min and 60 min). Velocity and Lineweaver-Burke plots are shown (left and right panels, respectively). KmATP was determined to be 2 μM +/− 0.2 μM ATP (S.D.) based on two independent experiments using three different preparations of the full length enzyme. (b) Equivalent ATP titrations and plots for the CDK12715–1052/CycK11–267 complex. KmATP was determined to be 25.5 μM +/− 0.01 μM ATP (S.D.) based on two independent experiments. (c) Full length CDK12/CycK1 activity was measured against varying concentrations of GST-CTD substrate using 10 μM ATP and a reaction time of 15 min. Experiments were performed in triplicate (velocity plot, left panel) and the average values plotted in a Lineweaver-Burke plot (right panel). KmCTD was determined to be 0.3 μM +/− 0.06 μM (S.D.). (d) Equivalent GST-CTD titrations for the CDK12715–1052/CycK11–267 complex. KmCTD was determined to be 2 μM +/− 0.7 μM (S.D.). Differences in the Km values between the full length and truncated CDK12 complexes suggest that other domains within the full length protein may contribute to substrate binding and turnover.
Figure 7 Determination of CDK12 kinetic parameters. (a) Full length CDK12/CycK1 activity was measured against varying concentrations of ATP over 3 time points (15 min, 30 min and 60 min). Velocity and Lineweaver-Burke plots are shown (left and right panels, respectively). KmATP was determined to be 2 μM +/− 0.2 μM ATP (S.D.) based on two independent experiments using three different preparations of the full length enzyme. (b) Equivalent ATP titrations and plots for the CDK12715–1052/CycK11–267 complex. KmATP was determined to be 25.5 μM +/− 0.01 μM ATP (S.D.) based on two independent experiments. (c) Full length CDK12/CycK1 activity was measured against varying concentrations of GST-CTD substrate using 10 μM ATP and a reaction time of 15 min. Experiments were performed in triplicate (velocity plot, left panel) and the average values plotted in a Lineweaver-Burke plot (right panel). KmCTD was determined to be 0.3 μM +/− 0.06 μM (S.D.). (d) Equivalent GST-CTD titrations for the CDK12715–1052/CycK11–267 complex. KmCTD was determined to be 2 μM +/− 0.7 μM (S.D.). Differences in the Km values between the full length and truncated CDK12 complexes suggest that other domains within the full length protein may contribute to substrate binding and turnover.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

Metadata

Authors
Dixon-Clarke, S. E., Elkins, J. M., Cheng, S.-W. G., Morin, G. B., & Bullock, A. N.
Affiliations
  • University of Oxford (GB)
  • BC Cancer Agency (CA)
Corresponding author
Bullock, Alex N.
Venue
Scientific Reports
Published
2015-11-24
Volume
5
Issue
1
Pages
17122-17122
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2177054638
Cited by
38
References
49
Citations by year
2026: 1 · 2025: 4 · 2024: 5 · 2023: 2 · 2022: 1 · 2021: 3 · 2020: 9 · 2019: 1 · 2018: 4 · 2017: 6 · 2016: 2
FWCI
1.74
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Eli Lilly and Company
  • Pfizer
  • GlaxoSmithKline
  • Genome Canada (1097737, OGI-055)
  • Wellcome Trust (106169/Z/14/Z, 092809, 106169, 092809/Z/10/Z, 1097737)
  • Diamond Light Source (mx8421, 1097737)
  • Ontario Genomics
  • Ontario Genomics Institute (OGI-055, 092809/Z/10/Z)
  • Ontario Ministry of Economic Development and Innovation (092809/Z/10/Z)
  • Ministero dello Sviluppo Economico
  • Natural Sciences and Engineering Research Council of Canada (1097737)
  • Medical Research Council
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
Keywords
CDK12, cyclin K, ATP binding, AMP-PNP, crystal structure, transcription elongation, RNA polymerase II C-terminal domain phosphorylation, kinase activity
MeSH terms
Adenylyl Imidodiphosphate, Animals, Humans, Hydrogen Bonding, Models, Molecular, Protein Binding, Solubility, Cyclins, Crystallography, X-Ray, Spodoptera, Cyclin-Dependent Kinases, Catalytic Domain, Protein Structure, Quaternary, Protein Interaction Domains and Motifs, Sf9 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.